Cipepofol

Cipepofol
Clinical data
Other names	Ciprofol; CS-0064163; CS0064163; GTPL10812; GTPL-10812; HSK-3486; HSK3486; HY-116152; HY116152; (R)-2-(1-Cyclopropylethyl)-6-isopropylphenol
Routes of; administration	Intravenous infusion
Drug class	GABAA receptor positive allosteric modulator
Pharmacokinetic data
Metabolism	Liver glucuronidation
Excretion	Kidney
Identifiers
	IUPAC name 2-[(1R)-1-cyclopropylethyl]-6-propan-2-ylphenol;
CAS Number	1637741-58-2 ;
PubChem CID	86301664;
DrugBank	DB16295 ;
ChemSpider	76794458 ;
UNII	M3WGS532VY;
KEGG	D12449 ;
ChEMBL	ChEMBL4094894 ;
Chemical and physical data
Formula	C14H20O
Molar mass	204.313 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@H](C1CC1)C2=CC=CC(=C2O)C(C)C;
	InChI InChI=1S/C14H20O/c1-9(2)12-5-4-6-13(14(12)15)10(3)11-7-8-11/h4-6,9-11,15H,7-8H2,1-3H3/t10-/m1/s1 ; Key:BMEARIQHWSVDBS-SNVBAGLBSA-N ;

Cipepofol (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name), also known as ciprofol or by its developmental code name HSK3486, is a general anesthetic related to propofol which is registered for clinical use in anesthesia and sedation. The drug is used by intravenous infusion. A short-acting and highly selective γ-aminobutyric acid positive allosteric modulator, ciprofol is 4 to 6 times more potent than other phenol derivatives such as propofol or fospropofol.

As of 2023, it is still an investigational drug. Manufactured by Haisco Pharmaceutical Group of Chengdu, Sichuan, China, ciprofol has undergone phase I and II trials in Australia and China. In these early studies, ciprofol appears to be comparable in efficacy to propofol and is associated with fewer adverse events.